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NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
Antibodies to Vascular Endothelial Growth Factor in
Non-small Cell Lung Cancer
Heather Wakelee, MD
Angiogenesis, formation of new vasculature, is critical to cancer
growth. Agents that block angiogenesis, in particular bevacizumab,
a monoclonal antibody that binds vascular endothelial growth factor,
the key ligand in angiogenesis, have become an important option for
many patients with non-small cell lung cancer (NSCLC). Activity
was first demonstrated in Eastern Cooperative Oncology Group
E4599, a large phase 3 trial that randomized patients with newly
diagnosed, nonsquamous NSCLC to receive carboplatin/paclitaxel
with or without bevacizumab at 15 mg/kg every 3 weeks. The study
demonstrated significant improvements in response rate, progres-
sion-free survival, and overall survival with the addition of bevaci-
zumab. Median overall survival improved from 10.3 to 12.3 months
(p  0.003). Significant toxic effects, including fatal hemoptysis,
however, resulted in 15 treatment-related deaths in the bevacizumab
arm. The beneficial results were recently confirmed in the European
Avastin in Lung Cancer B017704 (AVAiL) trial. In AVAiL, patients
with newly diagnosed nonsquamous NSCLC were randomized to
receive cisplatin/gemcitabine with or without bevacizumab at doses
of either 7.5 or 15 mg/kg every 3 weeks. Both doses resulted in
statistically significant improvements in response rate and progres-
sion-free survival, but overall survival results have yet to be pre-
sented. Based on these encouraging results, the drug is now being
studied in earlier-stage disease as neoadjuvant or adjuvant therapy
and in locally advanced NSCLC. Exploration of the safety and
efficacy of the drug in combination with other chemotherapeutics
and targeted agents, and in previously excluded patient populations
such as those with brain metastases, is also ongoing.
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Despite dozens of phase 3 trials of novel targeted agentscombined with first-line chemotherapy for advanced-
stage non-small cell lung cancer (NSCLC), the only positive
ones to date have been with bevacizumab (Avastin; Genen-
tech, South San Francisco, CA). Bevacizumab is a recombi-
nant humanized monoclonal antibody against the vascular
endothelial growth factor (VEGF),1 a key ligand in the
signaling cascade that leads to vascular formation. The suc-
cess of an antiangiogenesis drug is not surprising given the
dependence of solid tumor growth and metastases on neovas-
cularization.
Folkman first described the importance of tumor neo-
angiogenesis in tumor growth more than 30 years ago and
hypothesized that inhibition of this pathway could potentially
treat cancer.2 The selectivity of VEGF inhibition was pre-
dicted based on the exceptionally high levels of VEGF found
in many tumors and the uniqueness of the tumor vascula-
ture.3,4 Promising preclinical work with a VEGF antibody in
a murine model5,6 led to the development of the humanized
version, bevacizumab, and in 2003 the results of a random-
ized phase 3 trial demonstrating improved survival with the
addition of the drug to colorectal cancer therapy was
presented.7
E4599
The pivotal trial that demonstrated activity of bevaci-
zumab in the treatment of advanced-stage NSCLC was
E4599. The study randomized patients with previously un-
treated advanced-stage NSCLC to receive bevacizumab at 15
mg/kg every 3 weeks or no additional therapy in combination
with standard carboplatin and paclitaxel for six cycles.8
Bevacizumab was continued until disease progression based
on promising disease stabilization seen in initial phase 2
development.9 A total of 878 patients were entered into
E4599, and clear improvements in response rate, progression-
free survival (PFS), and overall survival were demonstrated
in the bevacizumab arm. To minimize bleeding risk, includ-
ing fatal hemoptysis that had been seen in the randomized
phase 2 trial, patients with squamous cell histologic findings,
brain metastasis, anticoagulant use, or history of gross he-
moptysis were excluded. Despite the precautions, 15 treat-
ment-related deaths occurred in the bevacizumab arm, five
due to hemoptysis, compared with only two treatment-related
deaths in the control arm. Common toxic effects with bev-
acizumab include hypertension, proteinuria, mild epistaxis,
and worsening neutropenia. Rare and potentially fatal com-
plications include bleeding, particularly hemoptysis, a revers-
ible posterior leukoencephalopathy syndrome, fistula forma-
tion, and surgical wound dehiscence. Despite these toxic
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effects, the clinical benefit demonstrated in E4599 is signif-
icant, especially when one considers the number of negative
trials with other targeted agents in this patient population. In
October 2006, based on the results of this trial, bevacizumab,
given in combination with carboplatin and paclitaxel, was
granted a labeling extension by the Food and Drug Admin-
istration for the initial treatment of advanced-stage NSCLC.
AVAiL
The benefit of bevacizumab in advanced-stage NSCLC
has now been confirmed in a second large randomized phase
3 trial, Avastin in Lung Cancer B017704 (AVAiL), presented
at the American Society of Clinical Oncology (ASCO) meet-
ing in June 2007.10 The trial was also limited to those patients
with untreated advanced-stage, nonsquamous NSCLC with-
out brain metastases, without invasion of tumor into major
vessels (although tumor in a central location was acceptable)
and not receiving anticoagulation. In total, 1043 patients were
enrolled in this study and randomized to one of three arms.
All patients received cisplatin and gemcitabine, and were
randomized to receive the chemotherapy with placebo, bev-
acizumab at 7.5 mg/kg, or bevacizumab at 15 mg/kg (the dose
used in E4599). Patients received up to six cycles of chemo-
therapy plus bevacizumab or placebo, which were then con-
tinued until disease progression. The primary endpoint was
PFS with disease evaluation every three cycles (9 weeks).
Both bevacizumab arms met the primary endpoint of im-
proved PFS compared with placebo. The hazard ratio for PFS
was 0.75 (95% confidence interval, 0.62–0.91; p  0.003) at
the 7.5 mg/kg dose and 0.82 (95% confidence interval,
0.68–0.98; p  0.03) at the 15 mg/kg dose. Response rates
were also significantly improved with bevacizumab. Overall
survival data have not yet been presented.
The toxicity data from the study were also reassuring.
Serious adverse events (including those leading to death) did
not differ between the placebo arm and the 7.5 mg/kg dose of
bevacizumab arm but were higher with the 15 mg/kg dose of
bevacizumab arm (1% higher death rate from serious adverse
events). Most of these fatalities were from hemoptysis. Cen-
tral tumor location and use of therapeutic anticoagulation
(allowed if started after patient was on trial) did not seem to
increase bleeding risk. The incidences of neutropenia, vom-
iting, hypertension, and epistaxis were also higher with the
addition of either dose of bevacizumab. Ischemic events
(including arterial thrombosis) and venous thromboembolic
events were not significantly changed with the bevacizumab
though.
OTHER COMBINATION TRIALS
Multiple other chemotherapeutic agents and targeted
therapies are also being combined with bevacizumab. Posters
given at the ASCO annual meeting in June 2007 included
three phase 2 studies of bevacizumab with different platinum
doublets. Dr. Patel presented preliminary results on 39 pa-
tients treated with bevacizumab at the standard 15 mg/kg
dose in combination with carboplatin and pemetrexed, with
an intriguing 55% response rate but some instances of bowel
perforation in patients with diverticular disease.11 Another
trial of first-line therapy examined the combination of carbo-
platin with nanoparticle albumin bound (nab)-paclitaxel plus
bevacizumab at 15 mg/kg, all given every 3 weeks.12 Initial
data on the first 50 patients have shown an encouraging
response rate and high median survival time of nearly 16
months. In the second-line setting, a combination regimen of
oxaliplatin, pemetrexed, and bevacizumab at 15 mg/kg every
3 weeks also showed very promising preliminary results in 32
patients.13 Ongoing bevacizumab/chemotherapy trials are
outlined in Table 1. None of the trials have reported unex-
pected safety concerns with the exception of bowel perfora-
tion in those with diverticular disease mentioned earlier.
The first targeted agent combined with bevacizumab is
the epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) erlotinib. A promising median survival time of
more than 12 months, observed for 34 patients treated with
this combination as second- or third-line therapy in the initial
phase 2 study led to further development.14 Another single-
arm phase 2 study, reported at ASCO 2007 enrolled 46
patients and found a 20% relative risk reduction but only a
7.9-month median survival time.15 A randomized phase 2
study of 120 patients on three treatment arms, either erlotinib
(150 mg daily) plus bevacizumab (15 mg/kg every 3 weeks),
chemotherapy alone (docetaxel or pemetrexed), or chemo-
therapy with bevacizumab, reported a 57% 1-year survival
for the erlotinib/bevacizumab arm, although the hazard ratios
for disease progression were not statistically improved by the
addition of bevacizumab.16 Genentech has opened two large
phase 3 studies with this drug combination, including the
Beta trial, which will include 650 patients who will receive
second- or third-line erlotinib with or without bevacizumab.
AVF3671g, commonly known as the “ATLAS” trial, is
enrolling patients to receive first-line doublet chemotherapy
plus bevacizumab then, after completion of four to six cycles
of chemotherapy, to continue bevacizumab with or without
erlotinib. Additionally, phase 2 trials of the combination are
ongoing as first-line therapy in selected patient populations,
such as those with a poor performance status, never-smokers,
bronchioloalveolar carcinoma, elderly patients (with pem-
etrexed as a third agent) and others.
Other targeted agents, including VEGFR-TKIs and the
EGFR antibody cetuximab, are also being studied in combi-
nation with bevacizumab, often with chemotherapy as well.
Table 2 includes many of these ongoing trials.
BEVACIZUMAB IN ELDERLY PATIENTS
AND WOMEN
Treatment of elderly patients with advanced-stage
NSCLC is an area of controversy. Some trials have cast doubt
on the benefit of doublet chemotherapy regimens in those
older than 70 years,17 whereas other trials have shown the
same magnitude of benefit with platinum doublets for older
versus younger patients.18 In the United States, many healthy
elderly patients receive standard doublet chemotherapy at
diagnosis of advanced-stage NSCLC. Many of these patients
also fit the eligibility criteria for bevacizumab and would be
considered for this therapy. An analysis of elderly patients in
E4599, however, argues for caution with this approach.19
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TABLE 2. Ongoing Trials of Bevacizumab with Targeted Agentsa
Treatment Sponsor/Location Phase Accrual Goal Line of Therapy
Erlotinib Genentech Beta 3 650 Second or third
Erlotinib Genentech ATLAS 3 1150 Immediately after first
Erlotinib vs. chemotherapyb Hoffman-La Roche 2 100–500 First
Erlotinib vs. gemcitabine/cisplatinb Germany 2 220 First
Erlotinib HOG 2 25 First—PS2
Erlotinib SWOG 2 80 First—BAC
Erlotinib SWOG 2 80 First—never-smokers
Erlotinib Switzerland 2 109 First
Erlotinib/pemetrexed H. Lee Moffitt 1/2 57 First-elderly
Apomab/carboplatin/paclitaxel Genentech 2 120 First
RAD001/carboplatin/paclitaxel Novartis 1 120 First
AMG951(rhAPO2L)/TRAIL/chemotherapyb Amgen 2 200 First
Enzastaurin/carboplatin/pemetrexedb Eli Lilly 2 90 First
Sunitinib/carboplatin/paclitaxel Genentech 2 130 First
Cetuximab/carboplatin/paclitaxel SWOG 2 90 First
Cetuximab/carboplatin/paclitaxel ImClone 2 120 First
Sorafenib/carboplatin/paclitaxel MD Anderson 1 60 First
Sorafenib NCI 1 62 Second
Bortezomib/carboplatin University of Massachusetts 1/2 55 First
Imatinib University of Washington 2 50 Immediately after first
a Data are from www.clinicaltrials.gov accessed on 10/1/2007.
b Not yet accruing.
BAC, bronchioloalveolar carcinoma; HOG, Hoosier Oncology Group; NCI, National Cancer Institute; PS2, performance status 2; SWOG, Southwest Oncology Group.
TABLE 1. Ongoing Trials of Bevacizumab with Chemotherapy
Treatment Location Phase Accrual Goal Line of Therapy
Cisplatin/vinorelbine, cisplatin/
gemcitabine, cisplatin/docetaxel
ECOG—Lung Intergroup 3 1500 Adjuvant
Cisplatin/docetaxel MSKCC 2 70 Preoperative
Any platinum doublet Hoffmann-La Roche 4 1000 First
Carboplatin/pemetrexed Northwestern 2 50 First
Carboplatin/pemetrexed Cooper Health 2 First
Oxaliplatin/pemetrexed Dana-Farber 2 50 Second
Carboplatin/gemcitabine Stanford 2 50 First
Carboplatin/gemcitabine Providence 2 45 First
Carboplatin/gemcitabine Minneapolis 2 48 First
Carboplatin/docetaxel MD Anderson 2 50 First
Oxaliplatin/gemcitabine Mt. Sinai, Miami 2 55 First
Oxaliplatin/docetaxel Sanofi-Aventis 2 75 First
Oxaliplatin/pemetrexed International Oncology Network 2 69 First
Gemcitabine/pemetrexed Karmanos 2 42 First
Topotecan University of Minnesota 2 60 Second
Pemetrexed/gemcitabine vs.
pemetrexed/carboplatin
Sarah Cannon 2 110 First—elderly
Pemetrexed/gemcitabine ACORN 2 48 First—elderly
Any chemotherapy Genentech 2 110 First or second—treated
brain metastases only
Pemetrexed Stanford 2 40 Second—treated brain
metastases only
Carboplatin/paclitaxel Genentech 2 40 First—squamous only
Data are from www.clinicaltrials.gov accessed on 10/1/07.
ACORN, Accelerated Community Oncology Research Network; ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan Kettering
Cancer Center.
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Ramalingam et al.19 analyzed patients in E4599 by age and
found that patients at least 70-year-old (approximately 25%
of total patient population) did not have the same survival
advantage with the addition of bevacizumab as their younger
counterparts but had higher toxicity rates. Results of a similar
analysis from AVAiL are awaited.
In an unplanned subset analysis of E4599, the hazard
ratio for overall survival for women was 0.98 (95% confi-
dence interval, 0.77–1.25), even though response rates (14%
versus 41%) and PFS were higher with the addition of
bevacizumab.20 No significant differences in second-line
therapy, including use of EGFR-TKIs, were identified that
could explain this survival discrepancy.8 Again, results of a
similar analysis from AVAiL are awaited. In colorectal can-
cer trials the survival benefits in women have equaled those
in men.21 The potential differences in survival by sex need
further exploration, but at this time the data do not support
differential prescribing of bevacizumab by sex.
EXPLORATION IN PREVIOUSLY
EXCLUDED POPULATIONS
Based on safety concerns, most trials with bevacizumab
in patients with NSCLC have excluded patients with squa-
mous cell histologic findings, known brain metastases, and
those receiving therapeutic anticoagulation. As outlined with
the AVAiL data, anticoagulation use can be considered cau-
tiously with NSCLC patients receiving bevacizumab, but the
study included small numbers of patients receiving anticoag-
ulation, and further exploration of the safety in this popula-
tion is warranted. Several ongoing trials are looking at the
drug in patients with treated, stable brain metastases. The
PASSPORT trial is a Genentech-led trial specifically in those
with treated brain metastases, and other trials such as ATLAS
allow for patients with treated brain metastases but do not
select specifically for them. The preliminary safety data from
42 patients treated on these two trials have been presented.22
Although central nervous system hemorrhages have not been
observed to date, one patient developed grade 3 leukoenceph-
alopathy.22 A phase 2 study at Stanford University is explor-
ing the use of bevacizumab in combination with pemetrexed
in patients with treated stable brain metastases. To overcome
the bleeding risk with squamous cell disease, two studies with
radiation before initiation of chemotherapy and bevacizumab
were begun, but were closed early due to toxicity concerns
(hemoptysis in particular). There are several trials of bevaci-
zumab that are proceeding cautiously, particularly in stage III
disease, that allow for squamous histology. Therefore, al-
though excluding those receiving anticoagulation or with
treated brain metastases may be unwarranted, squamous cell
disease may in fact be a true marker of an increased risk of
bleeding with bevacizumab.
EXPANSION TO OTHER STAGES OF DISEASE
Given the positive results with bevacizumab in patients
with advanced-stage NSCLC, several trials have opened
looking at the addition of bevacizumab to chemotherapy and
radiation for locally advanced NSCLC. Trials led by the
Southwest Oncology Group and the Sarah Cannon Cancer
Center have been frequently on hold because of concerns
about tracheoesophageal fistula formation, which has been
seen in trials of bevacizumab with concurrent chemoradiation
in limited-stage small cell lung cancer. A study at the Uni-
versity of North Carolina that includes bevacizumab with
carboplatin/paclitaxel/erlotinib and radiation remains open
but is being watched closely. In Europe, there is at least one
ongoing trial of radiation with escalating doses of bevaci-
zumab for NSCLC.
Bevacizumab is also being studied in early-stage, re-
sectable NSCLC. An ongoing trial at the Memorial Sloan
Kettering Cancer Center is examining bevacizumab alone or
in combination with cisplatin/docetaxel preoperatively.23 By
far the largest effort with bevacizumab in early-stage disease
though is the intergroup adjuvant trial, E1505 (Figure 1). This
study, which opened in June 2007, aims to enroll 1500
patients with completely resected stage IB (4 cm) to stage
IIIA NSCLC. Patients will receive four cycles of one of three
chemotherapy regimens (cisplatin/vinorelbine, cisplatin/do-
cetaxel, or cisplatin/gemcitabine) with randomization to be-
vacizumab at 15 mg/kg every 3 weeks, starting with the first
cycle of chemotherapy, for up to 1 year of therapy. Patients
are stratified by stage, histologic findings, sex, and chemo-
therapy regimen. Patients with any histologic findings are
eligible, as are those receiving anticoagulation. Extensive
correlative analyses are planned to help provide a better
understanding of both the biology of bevacizumab action and
which patients are mostly likely to benefit from this agent.
OTHER ANTIBODIES TO VEGF
Development of other antibodies that target VEGF has
not been as successful as the bevacizumab story. Consider-
able work was performed in Europe with HuMV833, but
because of dose-finding difficulties (nonlinear pharmacoki-
netics) and other issues, development is currently on hold.24
A slightly different approach has been taken with AVE0005,
commonly known as VEGF-TRAP, a chimeric fusion mole-
cule that contains portions of the extracellular domains of
VEGFR1 and VEGFR2 fused to the Fc portion of IgG1.25
This compound binds free VEGF and has shown early prom-
ise. When AVE0005 was used as a single agent at 4 mg/kg
every 2 weeks, two responses were seen in the first 34
patients enrolled in a phase 2 NSCLC trial, with accrual
ongoing.26 Ongoing randomized trials are examining this
agent in combination with docetaxel as well as with combi-
nation chemotherapy. Other agents are in earlier stages of
development.
CONCLUSIONS
Bevacizumab is the first agent to provide a survival
advantage when added to first-line chemotherapy for ad-
vanced-stage NSCLC. Its success in E4599 established the
importance of antiangiogenic strategies in the treatment of
NSCLC. The response rate and PFS benefit from this trial
have since been validated in a second large randomized trial,
and the drug is being studied in combination with an expand-
ing list of chemotherapeutics and with targeted agents. Stud-
ies in populations previously excluded, such as those with
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treated brain metastases, as well as in patient with early stage
disease, are also under way. The antibodies to VEGF, partic-
ularly bevacizumab, have opened a clear path for further
investigation of the role of antiangiogenic agents in NSCLC.
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